First North


Health Care

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, it develops tolerogens proteins technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.



Länk till dynamisk (zoombar) graf för större skärmar

Nuvarande och kommande formation

MA Rank

Rulla till toppen